Emisphere deal

The Hawthorne, N.Y., company terminated its option and license agreement with The Upjohn Co. to develop EMIS's proteinoid oral drug delivery system (PODDS) for human insulin. The companies were "unable to arrive at mutually agreeable terms for continued testing," EMIS said. ...